Figure 1.

Drugs with clinical potential in cancer that modulate miRNAs implicated in cell metabolism. In boxes are shown drugs that potentially modulate the main miRNAs involved in the metabolic reprogramming of tumor cells. Increased glycolysis flow, alteration of the PI3K/AKT/mTOR pathway, and epithelial-mesenchymal transition (EMT) are key processes that allow tumor cells to reprogram their metabolism in order to survive, proliferate, migrate, and evade new niches. Different miRNAs participate in these processes inhibiting the expression of enzymes (e.g., HK2, PKM2, IRS1, PI3K, AKT, mTOR), transcription factors (e.g., SP1, SIX1, ZEB1, ZEB2, GABPA), and cellular receptors (e.g., GLUT3, ESRRG).